These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 17430300)
1. Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications. Gianfrancesco F; Rajagopalan K; Goldberg JF; Wang RH Bipolar Disord; 2007 May; 9(3):252-61. PubMed ID: 17430300 [TBL] [Abstract][Full Text] [Related]
2. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. Jing Y; Kim E; You M; Pikalov A; Tran QV J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195 [TBL] [Abstract][Full Text] [Related]
3. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. Gianfrancesco FD; Rajagopalan K; Sajatovic M; Wang RH J Clin Psychiatry; 2006 Feb; 67(2):222-32. PubMed ID: 16566617 [TBL] [Abstract][Full Text] [Related]
4. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. Gianfrancesco F; Pesa J; Wang RH J Manag Care Pharm; 2005 Apr; 11(3):220-30. PubMed ID: 15804206 [TBL] [Abstract][Full Text] [Related]
5. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder. Zhu B; Kulkarni PM; Stensland MD; Ascher-Svanum H Curr Med Res Opin; 2007 Nov; 23(11):2805-14. PubMed ID: 17910804 [TBL] [Abstract][Full Text] [Related]
6. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. Hassan M; Madhavan SS; Kalsekar ID; Makela EH; Rajagopalan K; Islam S; Kavookjian J; Miller LA Ann Pharmacother; 2007 Nov; 41(11):1812-8. PubMed ID: 17925501 [TBL] [Abstract][Full Text] [Related]
7. Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: a retrospective study. Pae CU; Nassir Ghaemi S; Patkar A; Chae JH; Bahk WM; Jun TY; Masand P Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1322-5. PubMed ID: 16631294 [TBL] [Abstract][Full Text] [Related]
8. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis. Kim E; You M; Pikalov A; Van-Tran Q; Jing Y BMC Psychiatry; 2011 Jan; 11():6. PubMed ID: 21214937 [TBL] [Abstract][Full Text] [Related]
9. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Finkel S; Kozma C; Long S; Greenspan A; Mahmoud R; Baser O; Engelhart L Int Psychogeriatr; 2005 Dec; 17(4):617-29. PubMed ID: 16202186 [TBL] [Abstract][Full Text] [Related]
10. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914 [TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotics: newer options for mania and maintenance therapy. Vieta E; Goikolea JM Bipolar Disord; 2005; 7 Suppl 4():21-33. PubMed ID: 15948764 [TBL] [Abstract][Full Text] [Related]
12. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder. Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966 [TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics in the treatment of affective symptoms: a review. Masan PS Ann Clin Psychiatry; 2004; 16(1):3-13. PubMed ID: 15147108 [TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Olfson M; Gerhard T; Huang C; Lieberman JA; Bobo WV; Crystal S Schizophr Bull; 2012 Jun; 38(4):845-53. PubMed ID: 21307041 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK; Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435 [TBL] [Abstract][Full Text] [Related]
16. Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications. Gianfrancesco F; Wang RH; Pesa J; Rajagopalan K Int J Clin Pract; 2006 Nov; 60(11):1419-24. PubMed ID: 17073838 [TBL] [Abstract][Full Text] [Related]
17. Use of atypical antipsychotics in mood disorders. Weizman R; Weizman A Curr Opin Investig Drugs; 2001 Jul; 2(7):940-5. PubMed ID: 11757795 [TBL] [Abstract][Full Text] [Related]
18. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol. Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115 [TBL] [Abstract][Full Text] [Related]
19. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Perlis RH Am J Manag Care; 2007 Nov; 13(7 Suppl):S178-88. PubMed ID: 18041879 [TBL] [Abstract][Full Text] [Related]
20. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Gianfrancesco FD; Rajagopalan K; Sajatovic M; Wang RH Psychiatry Res; 2006 Nov; 144(2-3):177-89. PubMed ID: 17010448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]